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In treating malaria infections, rapid pharmacodynamic kill rates avert death and hinder 
drug resistance.  We explored the recent 4 decades of published P. falciparum 
monotherapy drug trials featuring over 17,000 patients from 355 study arms from which 
we could extract pharmacodynamic data related to parasite reduction.  Artemisinins 
represented 36%, methanolquinolines 27%, 4-aminoquinolines 20%, antifolates 10%, and 
antibiotics 7% of the useable trials.  The fold-decrease in parasite count in 48 hours after 
treatment (PRR) and the time to clear 50% of the parasites (PC50) were robust metrics 
because either can be used to reliably predict the other.  Other metrics like parasite 
clearance times (time to 90 or 100% clearance) or cure rate have clinical significance and 
are widely reported but provide little insight into pharmacodynamic rates. The critical 
first 48-hour PRR was around 5,100 for artesunate, 1,100 for quinine, 3,700 for 
chloroquine, 840 for sulfadoxine-pyrimethamine, 100 for atovaquone-proguanil, and 2 
for clindamycin and azithromycin. After an extended lag, the antibiotics had a maximum 
PRR of 5,700, leading us to consider the time at which each drug reaches its maximum 
kill rate.  All analyses were performed with the understanding that the trials had wide 
arrays of covariates such as initial parasitemia.  In Plasmodium, physiological changes 
spurred by quorum sensing at high parasite density could affect drug sensitivity or 
parasite clearance.  To better understand the effects of starting parasite density and 
quorum sensing on parasite kill rate, mouse models infected with P. berghei ANKA 
parasites expressing the GFP-luciferase reporter were treated with artesunate, 
amodiaquine, or pyronaridine at different times following infection.  Mice were treated 
beginning at roughly 10,000, 100,000, or 1,000,000 parasites/µL (during log growth) or 
on day 6, 8, or 10 after infection (during the plateau phase).  In subsequent arms, mice 
 iii 
were treated either before or after the projected “inflection point” between the log and 
plateau phases.  In general, mice treated during the plateau cleared parasites slower 
immediately following treatment, but overall clearance and outcome was not significantly 
affected.  This pattern was most exaggerated in artesunate, but there was also a notable 
distinction in mice treated with quinolines, especially at low doses. 
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Chapter 1: Pharmacodynamic analysis of kill rates in P. 
falciparum monotherapy clinical trials 
Introduction 
 Malaria remains a leading cause of morbity and mortality throughout much of the 
world, with over 200 million cases causing nearly half a million deaths in 2016.  The 
most severe form of human malaria is caused by Plasmodium falciparum, which causes 
most of the malaria-related mortality seen in patients in southeast Asia and nearly all 
malaria mortality in Sub-Saharan Africa. 
Most deaths from severe malaria occur within the first 24 to 48 hours of the onset 
of symptoms, so the prompt reduction of the parasite load within this window is essential.  
While numerous factors can play into the exact rate of parasite clearance, the drug 
administered is clearly the most important covariate affecting the rate and timing of the 
decline in parasitemia.  As such, we set out to collect existing data in an attempt to 
corroborate or refute existing paradigms regarding the rate of parasite clearance 
characteristic of each drug. 
 This study, inspired largely by two of Dr. Nicholas White’s reviews expounding 
the clinically-observed details of the malaria parasite clearance curve, consisted chiefly of 
compiling a large, if not exhaustive repository of clinical trial data and an initial analysis 
thereof.  The discussion of this undertaking will be divided into three parts: the anatomy 
of the clinical trials, the aggregated results of these trials, and the ultimate utility (or 
futility) of such an endeavor. 
 For the current project, we chose to focus only on monotherapy trials.  This could 
be a contentious decision, given that today, monotherapy is not recommended.  However, 
trials featuring monotherapy were selected for several reasons.  First, combination 
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therapies– especially experimental therapies that would be observed in clinical trials– 
contain multiple drugs that may be given in different ratios or schedules.  This further 
complicates the plethora of covariates to be considered that will be discussed.  Second, 
combinations of drugs may have effects on the kill rate that are not directly reflective of 
the constituent drugs; the partner drugs often enhace cure, but not clearance rate.  We 
thought the additional data was not worth what we sacrifice in clarity regarding each 
individual drug.  Finally, our lab uses murine models to study malaria drugs and 
regimens, and information regarding monotherapy will help to both ground these mouse 
studies in the human literature and inform future potential therapies to be tested in the 
mice by examining features of each drug that may be complementary. 
The anatomy of the malaria monotherapy trial 
Clinical trials, by their very nature, are interested primarily in the successes or 
failures of a treatment regiment.  This principle introduces two confounding factors into 
the analysis of the body of clinical trials.  The first, which is not specific to malaria, is the 
sui generis nature of every clinical trial.  There is little impetus to perform many trials 
with the same covariates, so each trial is, more or less, an island.  Features of the 
treatment– notably, the identity of the drug, its formulation and delivery method, the 
dose, the duration, and schedule– clearly affect the pharmacokinetics (PK) and/or 
pharmacodymanics (PD) in the patient and therefore have an undeniable effect on the 
outcome.  Disease-specific factors like the severity of the disease or the species and strain 
of the infecting parasites may alter interactions with patients and with drugs. 
Demographic characteristics, such as sex, age, location, patient immune status, and the 
dates of the trial could have affects on the results by altering PK/PD as well; some 
covariates may alter the pharmacodynamic kill rate of a drug by mechanisms that are 
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neither recorded in these trials nor fully understood.  Further, each study may use a 
different measure of central tendency and error term.  In this light, it is with great 
trepidation that anyone pools data from clinical trials, as it is unclear to what extent the 
trials are fully comparable. 
The second complication introduced by the central tenet of clinical trials as stated 
above is more specific to the treatment of malaria.  The circulating burden of malaria, 
unlike that of many other systemic infections, can be quantified to a reasonable degree of 
accuracy.  While this number does not represent the total body burden of total biomass 
because the percent sequestered at any point in time is not definable in P.falcipuarm 
infection, the estimate is nonetheless vital in that it is possible to observe differential rates 
of parasite clearance across different drugs in vivo.  Despite rate of clearance being 
undoubtedly important to physicians because of its correlation with clinical outcome, the 
paramount concern will always be patient recovery and survival.  As a result, many 
clinical trial reports– for reasons including, but not limited to, equipment or personnel 
restraints, financial concerns, or publication restrictions– forego either the collection or 
reporting of parasite clearance data and publish solely survival rates and other empirical 
results such as time to defervescence or coma resolution. 
Nevertheless, many authors of clinical trial reports do choose to report some 
measure of parasite clearance rate.  Clearance is usually defined by the average time to 
clear a predetermined percentage of parasites present at the beginning of treatment.  
These checkpoints are commonly 50% and 100% (or, more accurately, the time to absent 
detectable parasitemia), though 90%, 95% and 99% clearance times are also occasionally 
reported.  The initial parasite count is also reported, because it is assumed that these 
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clearance times are to some degree dependent on this level (i.e., clearance does not 
proceed in a first-order fashion).  The parasite reduction ratio, the ratio of parasites at the 
onset of treatment to that after 1 full life cycle (48 hours for P. falciparum) is arguably 
the most well-known metric for describing parasite clearance rates, but it is rarely 
reported directly.  Instead, it can be observed in a more robust descriptor of parasite 
clearance, which is the raw parasite count data depicted in an actual clearance curve. 
The aggregated results of the trials to be obtained 
 By analyzing the available data from several clinical trials of malaria 
monotherapy, we hoped to compile a small database of results from which we could draw 
rough conclusions regarding the early kill rates of each drug.  We attempted this by using 
some of the more commonly-reported metrics for parasite clearance, as well as devising 
new metrics that, while unrefined, could be used to describe empirically the rate of 
parasite clearance. 
Parasite clearance time (time to absent detectable parasitemia) is perhaps the simplest 
metric with clinical significance.  While it is commonly reported, it has limited utility in 
attempts to describe the clearance profile of any drug, because clearance time is 
necessarily related to initial parasitemia, with patients with lower initial parasite counts 
clearing their parasites earlier (White, 1997; Stepniewska et al., 2010).  The common 
geomean or average starting parasitemia also compresses the high and low initial 
parasitemias. 
 Parasite clearance is traditionally reported in a clinical setting as a clearance time 
or a parasite reduction ratio (PRR), but it must be acknowledged that a lag period 
following treatment is often observed, even to some degree in the fastest-acting drugs, 
artemisinin and its derivatives.  This lag period confounds clearance measures because 
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any simple numerical descriptor of clearance rate will simply connect point A to point B 
without regard for what happens between them.  The debate continues regarding whether 
this empirical approach is sufficient, as practitioners and patients alike remain dedicated 
to the reduction of the parasite load by any path necessary.  On the contrary, antimalarials 
are often described (and, of course, marketed) by the maximum rate at which they clear 
parasites; this measure is considered less variable and more indicative of the mechanism 
of action of the drug (White 2011), but ignores important features of a drugs’ PK/PD 
profile.  In severe cases when patients may not survive to the end of the lag period, it is 
not sufficient to claim that a drug will work rapidly, but not immediately.  The 
importance of the lag phase itself has been disputed.  Once cited as a positive prognostic 
indicator due to the presumed synchronicity of the infection (Gashot et al., 1996), an 
early rise in parasitemia following treatment is likely unrelated to outcome, though it is 
more common in complicated malaria (Silachamroon et al., 2001). 
 Reconciling these two measures– clearance time and PRR– may prove impossible 
without complex modeling of each drug, which has been started elsewhere, but not 
undertaken here.  Instead, we report both measures and will briefly consider the effects of 
each.  As will be discussed in the next section, these results are subject to scrutiny and 
will be the subject of more intensive analysis in the future.  For each of the results we 
find, there are dozens of correlations between covariates that we have yet to consider.  
The plethora of studies included in this study amounts to only a glimpse at the entire 
body of data freely available, but nonetheless the results are worthy of consideration. 
The utility of the results 
 Due to the issues described above, we must tread carefully when considering any 
implications of the data we recover from these analyses.  In addition, other studies may 
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throw into question the usefulness of studying the early kill rate of drugs at all.  For 
example, it has long been assumed that the early clearance rate following treatment is that 
which would have occurred anyway, depending on the age distribution of the infecting 
parasites and whether schizogony or sequestration would predominate at that time 
(White, 1997).  Khoury et al (2016) observed a significant positive correlation between 
the early parasite clearance rate following treatment and the growth rate 36 hours before 
treatment, even when parasite count decreased, indicating that kill rates are at least 
associated with, if not entirely dependent on, the growth cycle of the parasites before 
treatment.  Hoshen and colleagues’ (2000) model suggests that synchronicity is essential 
to the initial kill rate, and the more synchronous the infection, the faster the kill rate can 
be.  Both of these results are significant variables that cannot be observed in our data or 
any other extracted dataset. 
Immunity status may be the single largest factor affecting kill rate for any given 
drug, according to a multitude of studies in numerous locations (Lopera-Mesa et al., 
2013; Greenhouse et al., 2009; Hastings et al., 2015; White, 1997; Stepniewska et al., 
2010)  and while it can be estimated based on endemicity of the region in which a patient 
lives, it cannot be quantified precisely for data pooled into a clinical trial.  Geographical 
location is also an important factor in that it likely affects care-seeking behavior.  Not 
only are more remote patients more likely to progress to severe malaria, patients near 
care facilities are more likely to receive treatment immediately following schizogony-
induced fever (Mok et al., 2014).  Geographical distribution, parasite heterogeneity, 
patient age, and duration of study are factors that can affect immunity and treatment 
within any one trial, and these cofactors have yet to be accounted for in the present 
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analyses due to lack of data or an insufficient number of trials.  Further, enhanced 
immune status could increase clearance rates by supplementing the drug’s activity in 
either or both of the required actions for an observed reduction in parasite count– killing 
or splenic clearance of the parasites.  Depending on the exact mechanism of the apparent 
drug-immune system synergy, immune status may impart a different effect on each drug.  
We point out that we are not conducting a meta-analysis. 
 In the absence of evidence to contrary, we will carry on under the assumption that 
pooling the data will provide the most reliable estimate of kill rates in spite of all the 
potential confounders.  Our results will then be a nearly all-encompassing look at the 
various rate measures for each drug and will, at the very least, provide insight into the 
veracity of the assumptions in the field regarding the times, rates, and other 
characteristics of action for each drug.  A network meta-analysis may provide a more 
succinct, statistically-relevant look at the data in the future. 
 Drug resistance was not considered a confounder in our analyses.  First, parasite 
populations that are considered highly drug-resistant would not be treated with a 
monotherapy regimen of that drug.  In addition, in the event of developing resistance, 
Hastings et al (2015) demonstrated that resistance has little impact on clearance rates 
unless sensitivity is extremely low. 
 The parasite clearance estimator (PCE) is a tool available from the Worldwide 
Antimalarial Resistance Network (WWARN) that uses an algorithm to predict an 
appropriate parasite clearance curve given important covariates (Flegg et al., 2011).  
However, while repeated measures of parasitemia are required for input into the PCE 
(Jamsen et al., 2013), we aimed to describe the clearance profiles of antimalarials using 
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the metrics commonly available in the literature.  The PCE certainly represents a more 
comprehensive model based on only a few clinical trials than what we derived here, but 
its requirements are not often met in the field.  Rather than producing a complicated 
model, we aimed to describe the features of the parasite clearance curve itself, as well as 
some trends through time and space, in simply numeric terms such that the entire profiles 
of the drugs could be compared. 
Methods 
Data Collection 
 Data were collected from 185 studies treating over 17,000 patients with 
monotherapy regimens.  The dataset was compiled from searching databases for malaria 
monotherapy trials and from WWARN’s register of malaria chemotherapy trials.  
PubMed and Google Scholar search terms included, but were not limited to, “malaria 
monotherapy trial”, “falciparum chemotherapy”, and searches for trials for specific 
malaria drugs.  Then, the references of each selected paper were searched for relevant 
keywords.  The current analysis was not strictly a meta-analysis or systematic review. 
Inclusion Criteria 
 For a trial to be included in any analyses, it had to present at least one type of 
pharmacodynamic data: either a time at which a certain clearance threshold was met 
(commonly 50%, 90%, and absent parasitemia– PC50, PC90, and PCT respectively) or 
parasite counts at given times from which rates could be calculated.  When parasite 
counts were the only source of clearance data, parasite counts must be provided at least 
once per day for the first 48 hours.  GraphClick software was used to extract data points 
from graphs when PDFs of publications were available but the data itself was not 
provided. 
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 Due to the vast number of reports available online via the Welch Medical Library, 
publications that were not available online were not included.  Trials were also excluded 
if they featured no monotherapy treatment arms, infection with P. vivax (or mixed 
infections), or were not available in English.  Two exceptions were made for combination 
therapies– sulfadoxine-pyrimethamine and atovaquone-proguanil– because they are used 
almost exclusively in combination with each other, and the constituent drugs are almost 
always combined in roughly the same ratio. 
Metrics 
Authors of malaria clinical trials report a wide array of metrics to describe the 
effectiveness of malaria chemotherapeutic agents.  No metric for clearance rate was 
universal, which made comparison between trials difficult.  Many trials do not report any 
clearance data, opting only to describe the effectiveness of the drugs with respect to cure 
or ablation of specific symptoms, such as coma or fever; such trials were excluded from 
the present analysis as per the inclusion criteria.  The descriptors and metrics collected 
from each study are listed in Table 1.1.
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METRIC DESCRIPTOR EQUATION 
COUNTRY/REGION Country and region from which data was collected  
INITIAL PARASITEMIA (P0) Patient parasitemia measure at t0 (before treatment)  
ERROR Error surrounding previous value; could be one number 
(SD) or bounds (CI, RANGE) 
 
CENTRAL TENDENCY TYPE Reported measure of central tendency for previous value 
(e.g., MEAN, GEO. MEAN) 
 
ERROR TYPE Reported error surrounding previous value (e.g., range, 
SD, 95% CI) 
 
DOSE ADMINISTERED Amount of drug administered per dose; changes in dose 
throughout regimen denoted by "/" 
 
DOSES PER DAY Number of doses given per day; "/" corresponds with 




Length (in days) of treatment; "/" corresponds with 
changes in DOSE or FREQ 
 
FORMULATION/DELIVERY Formulation of drug and/or route of delivery  
TOTAL DRUG GIVEN Total amount of drug administered to a given time point DOSE*FREQ*days 
ABSOLUTE REDUTION 
RATE 
Decrease in percentage of initial parasitemia (P0) (P1-P0)/[(t1-t0)*100] 
PARASITES REMAINING Raw number of parasites remaining P(t) 
PARASITES CLEARED Raw number of parasites cleared (cumulative) Abs.rate*p0 (+abs.rate1*p1, etc) 
RELATIVE REDUCTION 
RATE 
Parasitemia reduction ratio in 24 hour span (P1/P0)/[(t1-t0)*100] 





Ratio of parasitemia at onset of treatment to parasitemia 
at 48 hours 
P0/p2 
PC1/2 (h) Calculated time to clear half of remaining parasites 
(based on decrease in 24 hour period) 
24/log2(fold.decrease) 
More robust calculation of PC1/2 accounting for 
paradoxical increases; number becomes more arbitrary 







Log transformation of fold decrease Log(fold.decrease) 
LOG REDUCTION (0-48) Log reduction in initial parasitemia in 1 life cycle (0-48 
h) 
Log(p0-p2) 
EST. PARASITES CLEARED Estimate of parasites cleared in 48 hours based on PC50 




PRR calculated based on PAR RED* P0/par.red* 
EST. PARASITES CLEARED Estimate of parasites cleared in 48 hours based on PC1/2 
as a half-life 
P0-p0/(48/pc1/2) 
PC50 Measured time to clear 50% of initial parasitemia  
EST. PC50 Interpolation of PC50 from clearance data y=50% 
EST. PARASITES CLEARED Estimate of parasites cleared in 48 hours based on 
PC50* as a half-life 
P0-P0/(48/PC50*) 
PC90 Measured time to clear 90% of initial parasitemia  
PCT Measured time to absent measurable parasitemia  
NUMBER OF PATIENTS Number of people treated  
CURE RATE Percentage of patients who remain clear of parasitemia 
(and symptoms) at end of follow up 
 
SURVIVAL RATE Percentage of patients who survive to end of study 1-MORTALITY 
RECRUDESCENCE Percentage of patients who recrudesce  
FOLLOW UP TIME Follow up time  
MINIMUM PC1/2 Minimum PC1/2 throughout treatment iterative calculations– 24/LOG2(P(N)/P(N+1)) 
MiNIMUM PC1/2 TIME Time at which minimum PC1/2 is reached  
MAXMUM PRR Maximum PRR thoughout treatment iterative calculations– P(N)/P(N+2) 
MAXIMUM PRR TIME Time at which maximum PRR is reached  
TLAG Estimate of lag time before drug is (maximally) 
effective 
iterative slopes– (Pn+1-Pn)/(tn+1-tn)=S; considered tlag 
if Sn/Smax<0.2 (before Sn/Smax>0.2 for 2 time points) 
ADJUSTED PC1/2 PC1/2 adjusted to exclude lag phase  
ADJUSTED PRR PRR adjusted to exclude lag phase  
Table 1.1  Name, description, and formula (when applicable) for metrics used in analyzing P. falciparum monotherapy clinical trial 
data
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Lag time was defined according to the PCE algorithm as the time until the log-
adjusted slope of the parasite clearance curve was greater than 20% of the maximum 
slope throughout observation (Flegg et al., 2011).  We added the provision that the slope 
must remain at or above 20% of the maximum slope for at least two consecutive data 
points.  Identification of the maximum slope was constrained such that the first point 
must occur when the parasite count is at least 10% of the initial count in order to avoid 
large slopes owing only to imprecision at such low parasite levels. 
Some other metrics, notably “PC1/2”, were devised specifically for this analysis to 
make data for each trial reporting clearance data more robust and comparable.  Finally, in 
order to ascertain the “ideal” effectiveness of a particular drug irrespective of its lag time 
(which may hinder its effectiveness in practice), “adjusted” and maximum PRR and PC 
½ were calculated to demonstrate rate excluding the lag period and the fastest rate 
throughout the regimen, respectively. 
PC1/2 was devised as a proxy for the commonly-reported PC50 for use in trials 
where PC50 is not available.  It operates under the assumption that, for early time points 
following treatment, parasite count follows a first-order decay pattern, wherein PC50 
becomes comparable to a half-life; such has been observed to be at least roughly true 
(Lopera-Mesa et al., 2013; Day et al., 1996).  PC1/2 can be calculated according to the 
following equation: 
 
Equation 1.1  PC1/2 
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PC1/2 is undefined when there has been a change in parasite count of less than 5% 
because of the large error that could result from extrapolation from such a small sample.  
In situations where the parasite count increases following treatment, the PC1/2 that would 
be calculated from the traditional formula is negative, which, if trials with paradoxical 
increases in parasite density are included in analyses, will artificially deflate the pooled 
PC1/2, creating the illusion of faster clearance.  As such, the opposite of the PC1/2 from the 
traditional equation is added to a baseline value representing the maximum PC1/2 value 
before the result becomes undefined.  In this way, a graph of PC1/2 vs. fold decrease in 
parasite count will appear continuous, save the small region wherein PC1/2 is undefined, 
and paradoxical increases are more accurately represented as slow clearances. 
 Pred* is calculated according to the same principle likening parasite clearance to 
radioactive decay.  In this case, when data describing parasite clearance through time are 
unavailable, the number of parasites eliminated was estimated from PC50 by the 
following equation: 
 
�� ∗ = �0 − �02 8�� 0 
Equation 1.2  Pred
* 
Where 48/PC50 signifies the number of half-lives that occur in 48 hours, so (1/2)48/PC50 
represents the fold decrease as a result of this level of “decay”; multiplication of this 
value by the initial parasite count should result in the number of parasites remaining after 




 Data for the various analyses were collected in the Prism GraphPad program, 
which performed the necessary calculations for each (GraphPad Prism version 7.0b for 
Mac).  Among the simple analyses we performed were comparisons of PRR, PC50, and 
percent of parasites remaining through time.  PC1/2 was calculated as a proxy for PC50 in 
trial arms that provided clearance data, while Pred* was calculated as an estimate of the 
number of parasites reduced over 48 hours given PC50.  Finally, analyses considering the 
lag phase involved consideration of both the magnitude and time of the maximum 
parasite clearance rate (as measured by PC1/2 or PRR).  Each analysis was conducted 
within specific drugs and within drug classes. 
 One specific analysis that was performed was to look for a relationship between 




5.0±0.5), and high+ (P0>10
5.5).  When data 
were available, PRRs for trials within each stratum were plotted.  Another visualization 
was created showing the distribution of times at which the kill rate was highest in each 
trial.  This allows comparison of drugs beyond raw rates, but instead contextualizes them, 
accounting for lag phases. 
 Statistical analyses have yet to be reliably performed for any analysis.  Just as the 
metrics reported vary greatly, so too do the error terms reported and the measures of 
central tendency.  It should be possible to approximately convert between these measures 
using some combination of formulae and bootstrapping methods, but we chose instead to 
simply treat each study arm as an individual mean, with an associated weight according 
to the number of participants, and use the standard deviation of these weighted means as 
the error terms in our analyses.  We feel this provides at least enough evidence for a 
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qualitative assessment of commonly held beliefs regarding the kill rate associated with 
malaria drugs and drug classes.  All analyses were performed with both weighted an 
unweighted means unless otherwise noted. 
Results 
Results of literature search 
 Our rudimentary literature search returned 164 trials with at least one study arm 
that satisfied the inclusion criteria.  Within these 164 trials, there were 355 monotherapy 
study arms and 17553 patients observed.  The drugs considered for analysis fell into 6 
groups, with atovaquone-proguanil (and, occasionally, each drug by itself) occupying its 
own, seventh group.  The classes, drugs, and abbreviations used for the drugs are 
delineated in Table 1.2. 
CLASS DRUGS (AND ABBREVIATIONS) 
Aminoquinolines Amodiaquine (AQ), Chloroquine (CQ), Pyronaridine (PYN) 
Antibiotics 
Azithromycin (AZ), Clindamycin (CL), Fosmidomycin 
(FOS),   
Antifolates Sulfadoxine-Pyrimethamine (SP) 
Artemisinins Artemisinin (ART), Artemether (AM), Artesunate (AS) 
Methanolquinolines Mefloquine (MQ), Quinine (QN) 





Table 1.2  Drugs featured in analyses of monotherapy trials.  Abbreviations from 
WWARN. 
 Of the 355 study groups used in at least one of our analyses, 49.9% (n=177) were 
from Southeast Asia and 47.0% (n=167) were from Africa.  The remaining studies were 
from South America (2.5%, n=10), listed no location (n=1), or were composed of 
travelers returning from both Southeast Asia and Africa (n=1).  Artemisinins were the 
most common drugs in these trials, composing 34.7% (n=123) of all study arms.  
Aminoquinolines composed 20.8% (n=75), antibiotics 4.8% (n=17), antifolates 8.5% 
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(n=30), methanolquinolines 23.7% (n=85), other hemozoin inhibitors 3.7% (n=14), and 
AV+PG or its substituent drugs 3.7% (n=14) of the remaining trial arms. 
 
Figure 1.1  Characteristics of studies included in the analysis.  a) Geographical 
distribution of monotherapy study arms, b) dates of publication of all reports 
contributing at least one study arm to the analyses, and c) frequency of each drug class 
having been used in a monotherapy study arm 
 The drug regimens we encountered are described in Table 1.3.  To avoid 
decreasing sample sizes by stratification, we were forced to adopt the assumption that all 
doses, durations, and schedules of drug administration provide similar kill rates.  While 
this may not be strictly true, it can be justified to some degree in that patients are unlikely 















1.67 5 2, 2, 5, 5, 5 37 
8.3 6 1, 1, 1, 1 ,1 ,1 30 
8.33 5 1, 1, 1, 1, 1 40 
10 
2 2, 1.33 18 
3 
1, 0.5, 0.5 10 
2, 1.33, 1.33 32 
12 3 2, 1.25, 1 30 
16.67 
2 1, 1 10 
3 1, 1, 1 20 
40 4 1.33, 0.5, 0.5, 0.5 37 
Artemether 
1.6 6 2, 1, 1, 1, 1, 1 23 
2.67 
5 1, 0.5, 0.5, 0.5, 0.5 86 
7 1, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5 15 
3.2 
3 1, 0.5, 0.5 83 
4 1, 0.5, 0.5, 0.5 308 
5 1, 0.5, 0.5, 0.5, 0.5 193 
3.33 
2 2, 1 31 
4 1.5, 0.5, 0.5, 0.5 34 
5 1, 0.5, 0.5, 0.5, 0.5 81 
4 7 1, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5 60 
5 5 1, 0.33, 0.33, 0.33, 0.33 13 
10.67 7 3, 3, 3, 3, 3, 3, 3 14 
Artesunate 
1 3 2, 2, 1 31 
1.6 5 1.5, 1, 1, 1, 1 25 
1.67 
5 
1.5, 0.5, 0.5, 0.5, 0.5 40 
1.5, 1, 1, 1, 1 25 
2, 1, 1, 1, 1 25 
6 1, 2, 2, 2, 2, 2 20 
2 7 1, 1, 1, 1, 1, 1, 1 187 
2.4 6 1.5, 1, 1, 1, 1, 1 40 
3 4 1, 0.67, 0.67, 0.67 37 
3.33 3 1, 1, 1 68 
4 
3 1, 1, 1 30 
7 1, 1, 1, 1, 1, 1, 1 120 
6 7 1, 1, 1, 1, 1, 1, 1 51 
6.67 
5 1, 0.5, 0.5, 0.5, 0.5 45 
7 1, 0.5, 0.5, 0.5, 0.5, 0.5, 0.5 46 
10 1 1 114 
Mefloquine 
5.4 1 1 12 
8.33 1 1 90 
10.4 1 1 15 
12.5 
1 1 155 
1 1.33 50 
1 1.67 103 
15 1 1 40 
16.67 1 1 162 
20 1 1 47 
20.83 1 1 215 
21.2 1 1 8 
25 1 1 664 
30 1 1 42 
Quinidine 10 7 3, 3, 3, 3, 3, 3, 3 33 
Quinine 
8 3 3, 3, 3 22 
8.3 7 3, 3, 3 22 
8.33 
3 3, 3, 3 10 
7 3, 3, 3, 3, 3, 3, 3 30 
14 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3 24 
 18 
9 
3 3, 3, 3 3 
7 3, 3, 3, 3, 3, 3, 3 11 
10 
1 3 30 
5 3, 3, 3, 3, 3 21 
7 3, 3, 3, 3, 3, 3, 3 360 
8 3, 3, 3, 3, 4.5, 4.5, 4.5, 4.5 33 
10.8 10 3, 3, 3, 3, 3, 3, 3, 3, 3, 3 58 
12 
7 3, 3, 3, 3, 3, 3, 3 12 
2 2, 1 37 
3 2, 2, 2 31 
16 7 2, 1.5, 1.5, 1.5, 1.5, 1.5, 1.5 50 
20 5 1.5, 0.5, 0.5, 0.5, 0.5 288 
  7 2, 1.5, 1.5, 1.5, 1.5, 1.5, 1.5 394 
Halofantrine 
1 1 3 12 





8.33 1 3 112 
10 1 2 42 
16.67 1 1.5 20 
25 1 1 50 
Pyrimethamine 1.25 1 1 24 
Sulfadoxine+Pyrimethamine 
(16.67)+(0.83) 1 1 52 
(25)+(1.25) 
1 1 1094 
2 1.67, 0.67 21 
(25)+(1.5) 1 1 40 
(35)+(1.75) 1 1 28 
(35)+(2) 1 1 44 
Amodiaquine 
6.67 4 2, 1, 1, 1 24 
10 
2 
1, 0.5 22 
1.67, 0.67 47 
3 
1, 0.75, 0.75 25 
1, 1, 0.5 185 
1, 1, 1 182 
1.5, 0.5, 0.5 17 
4 1, 0.5, 0.5, 0.5 14 
15 3 1, 0.67, 0.67 84 
Chloroquine 





2 2, 1 19 
3 
1, 1, 0.5 1312 
1, 1, 1 106 
1.5, 0.5, 0.5 91 
15 3 
1, 0.67, 0.67 39 
1, 1, 1 41 
16.67 3 1.5, 1.5, 0.5 18 
16.7 3 1, 1, 1 16 
20 3 1, 1, 0.5 66 
Pyronaridine 
5 5 2, 1, 1, 1, 1 101 
8 3 2, 1, 1 81 
Atovaquone 12.5 
2 3, 1 25 
7 3, 3, 3, 3, 3, 3, 3 23 
Atovaquone+Proguanil 
(8.33)+(3.33) 
2 2, 1 24 
3 2, 2, 2 30 
5 2, 2, 2, 2, 2 24 
(12.5)+(4.17) (2)+(7) (3, 1)+(1, 1, 1, 1, 1, 1, 1) 25 
(12.5)+(5) 3 1, 1, 1 55 
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(16.67)+(6.67) 3 1, 1, 1 196 
(17)+(7) 3 1, 1, 1 30 
(20)+(8) 3 1, 1, 1 92 
Proguanil 8.33 3 2, 2, 2 13 
Azithromycin 16.7 3 1, 1, 1 16 
Clindamycin 
5 5 
1, 1, 1, 1, 1 44 
2, 2, 2, 2, 2 111 
7.5 3 3, 3, 3 12 
10 5 2, 2, 2, 2, 2 12 
Fosmidomycin 
20 
3 3, 3, 3 10 
4 3, 3, 3, 3 8 
5 3, 3, 3, 3, 3 9 
7 3, 3, 3, 3, 3, 3, 3 35 
30 5 2, 2, 2, 2, 2 24 
Table 1.3  Description of all monotherapy treatment regimens present in included trial 
reports (where sufficient data were available; 74 arms lacked duration of treatment– 
mostly those recovered from WWARN Parasite Clearance Study Group’s meta-analysis 
[2015]– and one lacked a sample size). 
 The variables reported in the included trials are shown in Table 1.4.  Because the 
metrics given were a significant component of the inclusion criteria for the analyses, the 
values shown are not representative of the entire body of malaria chemotherapy literature.  
Instead, they are only a description of the metrics reported provided that at least one 
clearance measure was given.  
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Initial parasite count 11 100.00% 20 95.24% 88 96.70% 35 92.11% 1 100.00% 40 90.91% 
  n=254 100.00% n=969 77.09% n=6458 97.98% n=1535 93.60% n=33 100.00% n=1571 80.19% 
Parasitemia 
measurements 
5 45.45% 9 42.86% 7 7.69% 12 31.58% 0 0.00% 15 34.09% 
  n=80 31.50% n=549 43.68% n=319 4.84% n=478 29.15% n=0 0.00% n=666 34.00% 
PC50 8 72.73% 7 33.33% 82 90.11% 2 5.26% 0 0.00% 16 36.36% 
  n=214 84.25% n=540 42.96% n=6249 94.81% n=315 19.21% n=0 0.00% n=1196 61.05% 
PC90 3 27.27% 5 23.81% 79 86.81% 2 5.26% 0 0.00% 12 27.27% 
  n=85 33.46% n=503 40.02% n=6179 93.75% n=315 19.21% n=0 0.00% n=1137 58.04% 
PCT 11 100.00% 20 95.24% 25 27.47% 32 84.21% 1 100.00% 40 90.91% 
  n=254 100.00% n=969 77.09% n=951 14.43% n=1190 72.56% n=33 100.00% n=1889 96.43% 












Cure rate 5 45.45% 10 47.62% 25 27.47% 32 84.21% 0 0.00% 21 47.73% 
  n=119 46.85% n=336 26.73% n=1105 16.77% n=1065 64.94% n=0 0.00% n=740 37.77% 
Recrudescence (RI) 
rate 
8 72.73% 12 57.14% 23 25.27% 30 78.95% 1 100.00% 23 52.27% 
  n=216 85.04% n=384 30.55% n=869 13.18% n=1000 60.98% n=33 100.00% n=775 39.56% 
                          
 Total 11 21 91 38 1 44 
   n=254 n=1257 n=6591 n=1640 n=33 n=1959 











Initial parasite count 10 71.43% 1 100.00% 26 89.66% 14 93.33% 44 84.62% 4 100.00% 
  n=453 71.11% n=24 100.00% n=1089 84.55% n=531 88.50% n=1621 154.82% n=182 100.00% 
Parasitemia 
measurements 
6 42.86% 0 0.00% 8 27.59% 5 33.33% 30 57.69% 2 50.00% 
  n=336 52.75% n=0 0.00% n=261 20.26% n=162 27.00% n=1118 106.78% n=101 55.49% 
PC50 2 14.29% 0 0.00% 0 0.00% 0 0.00% 2 3.85% 2 50.00% 
  n=160 25.12% n=0 0.00% n=0 0.00% n=0 0.00% n=34 3.25% n=101 55.49% 
PC90 2 14.29% 0 0.00% 0 0.00% 0 0.00% 1 1.92% 0 0.00% 
  n=160 25.12% n=0 0.00% n=0 0.00% n=0 0.00% n=15 1.43% n=0 0.00% 
PCT 11 78.57% 1 100.00% 23 79.31% 13 86.67% 31 59.62% 4 100.00% 
  n=398 62.48% n=24 100.00% n=1049 81.44% n=516 86.00% n=1198 114.42% n=182 100.00% 












Cure rate 11 78.57% 1 100.00% 25 86.21% 15 100.00% 30 57.69% 4 100.00% 
  n=427 67.03% n=24 100.00% n=966 75.00% n=600 100.00% n=1340 127.98% n=182 100.00% 
Recrudescence (RI) 
rate 
8 57.14% 1 100.00% 21 72.41% 13 86.67% 25 48.08% 4 100.00% 
  n=391 61.38% n=24 100.00% n=763 59.24% n=496 82.67% n=1097 104.78% n=182 100.00% 
                          
 Total 14 1 29 15 52 4 
   n=637 n=24 n=1288 n=600 n=1047 n=182 
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Initial parasite count 2 100.00% 9 90.00% 1 100.00% 1 100.00% 7 100.00% 7 100.00% 
  n=48 100.00% n=421 88.45% n=13 100.00% n=16 100.00% n=179 100.00% n=86 100.00% 
Parasitemia 
measurements 
0 0.00% 3 30.00% 0 0.00% 1 100.00% 5 71.43% 1 14.29% 
  n=0 0.00% n=176 36.97% n=0 0.00% n=16 100.00% n=155 86.59% n=12 13.95% 
PC50 0 0.00% 1 10.00% 0 0.00% 0 0.00% 0 0.00% 1 14.29% 
  n=0 0.00% n=30 6.30% n=0 0.00% n=0 0.00% n=0 0.00% n=20 23.26% 
PC90 0 0.00% 1 10.00% 0 0.00% 0 0.00% 0 0.00% 1 14.29% 
  n=0 0.00% n=30 6.30% n=0 0.00% n=0 0.00% n=0 0.00% n=20 23.26% 
PCT 2 100.00% 10 100.00% 1 100.00% 0 0.00% 3 42.86% 6 85.71% 
  n=48 100.00% n=476 100.00% n=13 100.00% n=0 0.00% n=50 27.93% n=74 86.05% 












Cure rate 2 100.00% 10 100.00% 1 100.00% 1 100.00% 4 57.14% 6 85.71% 
  n=48 100.00% n=476 100.00% n=13 100.00% n=16 100.00% n=97 54.19% n=74 86.05% 
Recrudescence (RI) 
rate 
0 0.00% 4 40.00% 0 0.00% 1 100.00% 4 57.14% 3 42.86% 
  n=0 0.00% n=257 53.99% n=0 0.00% n=16 100.00% n=97 54.19% n=47 54.65% 
                          
 Total 2   10   1   1 7 7 
   n=48   n=476   n=13   n=16 n=179 n=86 
 
Table 1.4  Metrics reported according to treatment.  Total number of study arms and total patients treated (n) are given for each 
drug/metric combination; percentages are percent of total study arms or total patients treated for a given drug.
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Parasite Clearance Time 
 PCT, as has been discussed previously, is one of the less robust clearance 
measures.  Nevertheless, it is the most common clearance metric reported in the 
literature, so we report the PCT for each drug group in Figure 1.2.  Artemisinins were, by 
far, the fastest to clear all detectable parasites.  Antibiotics, such as clindamycin and 
fosmidomycin, were the slowest group; however, all other drug groups were fairly close 
with regard to PCT. 
 
Figure 1.2  Time to absent detectable parasitemia, based on weighted means in each 
drug group 
Parasite reduction ratio 
 Looking at the classes as a whole, the artemisinins were the fastest killing drug 
class with a PRR of over 10000, though artemether was notably faster than the other 
drugs in the class.  Methanolquinolines and halofantrine had nearly the same PRR, with 
the aminoquinolines only slightly slower.  Antifolates, atovaquone-proguanil, and 
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antibiotics were the slowest (Figure 1.3).  It should be noted that the error terms shown 
are simply a standard deviation of the weighted means, as no error terms were available 
for most of the data from which our values were calculated.  As such, we were forced to 
treat each result as one (weighted) mean and report the error based on the variability of 
those means. 
 No significant differences in PRR were observed when the same analysis was 
performed without regard for the size of the studies.  This unweighted analysis was used 
to perform a D’Agostino & Pearson normality test to check if the PRR values obtained 
within each drug were log-Normally distributed.  Of the drugs with a sufficiently large 
number of trials (AM, AS, MQ, QN, SP, and CQ), only CQ deviated significantly from a 
log-Normal distribution (α=0.05).  A ROUT test to identify outliers (Q=1%) identified 




Figure 1.3  PRR results for each drug and drug class.  Vertical lines separate the drug 
classes.  Each point represents one study arm, with its shape signifying the size of the 
arm. 
 The results following stratification according to initial parasitemia were 
confounding.  There was no universal trend wherein a higher initial parasite count was 
associated with faster or slower clearance.  In some cases, there was no difference 
between strata (such as ART); in others, higher parasitemias tended to yield higher PRRs 
(e.g., CQ); in yet others, higher parasitemias were associated with lower kill rates (e.g., 
AS).  In order to reduce the effect of multiple doses on PRR, while also reducing the 
impact of the lag phase, we chose to calculate a 24-hour PRR.  These data are presented 
in Figure 1.4a.  Whereas PRR is traditionally calculated across the first 48-hour life cycle 
following initiation of treatment, we thought it may also be informative to consider 
maximum PRR, calculated across whichever 48-hour span featured the largest fold-
decrease in parasite count.  When looking at the data this way, many of the trends within 
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a given drug are the same, but PRR still failed to correlate with starting parasite count in 




Figure 1.4  PRR, stratified by initial parasite count.  Strata are centered around 1000 
(lo), 10000 (med), 100000 (hi), and 1000000 (hi+) parasites/μL (on a logarithmic scale).  
Drugs were excluded if all available trials fell into one stratum (PYN, AZ, FOS). a) initial 




Evaluation of new metrics 
 Neither PC1/2 nor Pred* were considered reliable substitutes for PC50 or the 
number of parasites cleared, respectively.  PC1/2 was highly accurate in a select few cases, 
but in general, when comparing trials with sufficient data to compare PC1/2 and PC50, 
PC1/2 was off the mark in a non-systematic way.  Future attempts to mathematize parasite 
clearance in this way may need to make adjustments for covariates that, for this 
preliminary attempt, were ignored.  For the remainder of this study, where PC1/2 is used, 
it is only used for its robustness in describing parasite clearance curves compared to PRR, 
rather than as a replacement for PC50. 
  Pred* was far more accurate than was PC1/2 when compared to studies with both 
PC50 and clearance data available; almost all of the studies exhibited less than 10% error, 
while none exceeded 18% error.  While these discrepancies are smaller than those seen 
when assessing PC1/2, they do not instill confidence that PC50 can reliably allow the 
calculation of parasites cleared in every case (Figure 1.5). 
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Figure 1.5  Percent error of a) PC1/2 and b) Pred*, where the calculated value (PC1/2 
and Pred*) is the observed value and the value derived from the reported data (PC50 
and the number of parasites cleared) is the theoretical value.  All trials where PC50 and 
clearance data were available were included; no correlation between percent error and 
drug or drug class was found. 
 When we considered PC1/2 on days 1, 2, and 3, most drug classes seem to exhibit 
higher and more variable PC1/2 values on day 1 than on subsequent days following 
treatment (Figure 1.6).  This is largely reflective of the lag phase, which may delay 
clearance for all or part of the first day following treatment.  Therefore, fast-acting drugs 





Figure 1.6  PC1/2 for each drug class based on clearance during day 1 (0-24 hours), day 
2 (24-48 hours), and day 3 (48-72 hours) 
 To begin to further explore the potential utility of Pred*, we calculated PRR from 
these values and plotted these estimates, as a whole, next to PRRs from clearance data for 
the artemisinins (Figure 1.7). PRRs calculated from Pred* were satisfactorily similar to 
those calculated from clearance data for artemisinin, but they were far too low compared 
to the average for artemether and artesunate.  However, PRR for both artesunate and 
artemether seem to be clustered into 2 groups– one with very high PRRs, and one with 































































































lower PRRs that seem to match the majority of those estimated from Pred*.  A preliminary 
look at the covariates associated with the studies from which we obtained actual PRRs 
revealed that 4 out of 5 of the studies with high PRRs featured some level of complicated 
malaria and 2 out of 5 had some comatose patients; 2 out of the 4 lower-PRR studies had 
severe malaria patients, but none were in comas.  Complicated malaria is usually treated 
differently than uncomplicated; notably, patients tend to be treated with IM injections 
because they cannot take medication orally.  The difference in patient state, drug 
formulation, and drug delivery could have significant effects on pharmacokinetics and 
pharmacodynamics, but these distinctions fail to totally explain the wide gap in PRR 
values; the same trend does not hold for the similar gap in artesunate PRR values.  
Nonetheless, they could be suggestive of an impact from covariates.  If this is the case, 
perhaps the estimated PRR values are, in fact, more representative of the body of data 
within a given drug than was initially thought. 
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Figure 1.7  PRR for ART, AM, and AS compared to PRR estimated from Pred* (via 
PC50), represented as stars. 
Lag phase 
 Lag time was a confounder in some drug classes, especially the antibiotics; the 
aminoquinolines also tend to have lag times, though not as long as antibiotics.  Lag phase 
was present to some degree in every drug class (Figure 1.8). 
 The drug may be only moderately effective or totally ineffective during the lag 
phase, so ignoring the lag phase altogether means that the action (or inaction) of the drug 
before it becomes fully effective would be discounted.  Instead, it was useful to look at 
when a drug reaches a maximum kill rate, which would factor in a lag phase should one 
be present.  Most drugs’ maximum rate (or minimum PC1/2) centered around day 1, with 
artesunate and fosmidomycin acting faster and clindamycin and azithromycin much 
slower (Figure 1.9).  The distribution of Tmax, or the time at which clearance is the fastest, 
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for each drug was fitted to a Gaussian distribution by GraphPad Prism, with amplitude 
constrained to 1 and mean constrained to ≥0. 
 
Figure 1.8  Lag times associated with each drug and drug group. 
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Figure 1.9  Calculation of PC1/2, iteratively across 24-hour spans, compared to the 
minimum PC1/2 across any 24-hour span; where each line touches 1 represents the time 
at which clearance was the fastest.  Gaussian curve above each graph indicates 
normalized distribution of Tmax, or the time at which each trial is fastest, for each drug. a) 
artemisinins, b) methanolquinolines, c) halofantrine, d) antifolates, e) aminoquinolines, f) 
atovaquone-proguanil, g) antibiotics.  In g), the only trial available for FOS exhibited 
cure within 24 hours, so only one point could be calculated. 
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 With the exception of the antibiotics, all drug groups tend to reach their fastest 
point around day 1 following treatment.  Unfortunately, this is likely, at least in part, an 
artifact of this time point being universal across all trials.  However, also interesting and 
potentially useful is the spread in Tmax within a drug; for example, while the maximum 
kill rate of CQ occurs almost anywhere across this 4-day span, the maximum kill rate for 
AQ occurs fairly predictably at 1 day following treatment.  Further investigation may 
elucidate whether the magnitude and variability of Tmax is due to pharmacokinetics or 
pharmacodynamics, and this information could be useful in characterizing drugs and 
devising new combinations. 
Geographical and temporal comparisons 
 PRR was stratified by region to observe any trends between Africa and southeast 
Asia (Figure 1.10).  MQ, QN, and AM were the only drugs to be used at an appreciable 
level on both continents.  Owing to the large standard deviation due to the use of 
weighted means, statistical tests failed to identify a significant difference in drug activity 
between either continent.  However, it appears that PRR is slightly higher in Africa than 
southeast Asia.  It is likely this difference is largely due to more ubiquitous immunity in 
Africa, but this may be a trend worthy of future investigation. 
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Figure 1.10  PRRs of MQ, QN, and AM in both Africa (AFR) and southeast Asia (SEA). 
 Most drugs exhibited an increase in PRR throughout time, which runs counter to 
that which may be expected with the development of resistance to some drugs (Figure 
1.11).  Hastings et al (2015) argued that clearance rates are insensitive probes for 
resistance, which may explain this negative finding; alternatively, these results could be 
subject to bias due to the fact that a drug is less likely to be given as monotherapy once 
resistance is suspected. 
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Figure 1.11  PRR through time in both Africa (AFR) and southeast Asia (SEA); only MQ 
in southeast Asia, ART in southeast Asia, and AM in Africa exhibited decreases in PRR 
through time; a) artemisinins, b) methanolquinolines, c) aminoquinolines. 
Discussion 
 
 The discussion of the data, like the the introduction, will be broken into three 
sections, each dedicated to different, yet equally important observations made throughout 
the collection and analysis of this dataset. 
The anatomy of the malaria monotherapy trial 
 The usability of the results in the average clinical trial report left much to be 
desired.  Many publications reported no measure of parasite clearance whatsoever, and 
for those that did, there was no universal metric.  In addition, there was no universal 
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measures of central tendency or error either, making comparison across trials difficult.  
While logistical concerns with the data collection may, to some extent, dictate the types 
of results that can be reported, the measures of central tendency and error should be 
ubiquitous.  We recommend geometric mean and standard deviation for all measures of 
parasite density, and mean and standard deviation for all other measures.  
Pharmacodynamic results 
 Most of our results are relatively unsurprising given the empirical rules of thumb 
already known to those that utilize and research malaria therapeutics.  The trends we 
found in the magnitude of PRR and PCT were largely what we expected; the variation 
within each drug, however, warrants further examination.  In addition, we tried to devise 
more robust metrics to utilize more of the body of clinical trial data, but these new 
measures need fine-tuning.  Other analyses, such as the consideration of the timing and 
magnitude of the maximum kill rate for each drug, were relatively unique and could 
provide quantitative insight into the pharmacodynamic actions of a drug. 
Parasite Reduction Ratio 
 While our results are the product of analyzing an amalgamation of trials featuring 
different populations, routes of administration, and other covariates, the average PRR 
values for each drug are relatively unsurprising compared to that which is traditionally 
expected.  For example, artemisinin and its derivatives have been touted as capable of a 
104-fold drop in parasite count over a single life cycle.  While artesunate and artemether 
occasionally reach this threshold, artemisinin does not.  Perhaps surprisingly, quinine and 
chloroquine also sometimes reach this level. 
 Parasite reduction ratio remains the primary metric for describing parasite clearance 
rates, though its merits have been questioned.  For example, PRR is statistically unrelated 
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to the growth of the parasite during the first few hours immediately following drug 
administration, during which time parasite growth is known to be more closely associated 
with growth patterns prior to treatment than the identity of the drug administered (Hastings 
et al., 2015).  Nevertheless, at this time, PRR must be sufficient for at least qualifying, if 
not quantifying, drug kill rates.  Based on this measure, it is clear that the artemisinin 
derivatives are associated with the highest PRR  despite the wide variation. 
Parasite Clearance Times 
 Time to absent detectable parasitemia (PCT), while potentially useful within trials 
for comparing study arms, is subject to many variables that make it less reliable as a 
comparator between trials.  Determination of the time at which parasites have been 
cleared will always be subject to some random action at the tail end of the parasite 
clearance curve, as the dwindling parasite population and/or drug concentration affect the 
predictability of their successful interaction.  Additionally, the resources available to the 
researchers may vary across studies and could exacerbate any uncertainties.  The use of 
thick or thin blood smears, the experience of the microscopist, and the number of fields 
observed are some factors that may not be universal across many studies.  The use of 
PCR makes observation much more sensitive, and thus, will extend PCT. 
 We feel that PC50 is a somewhat more reliable metric for quantifying clearance 
times.  While it it less clinically relevant, the larger number of parasites means that we 
should feel more confident in the relative accuracy of the measurements.  Also, for better 
or worse, it is less likely to be related to antimalarial resistance.  For our analyses, we 
prefer measurements that are less affected by resistance, as we were interested in 
considering the potential of a drug, not its actual effectiveness, which will vary according 
to geographic and temporal variables that have not been considered yet. 
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New Metrics 
 Unfortunately, none of the metrics devised to describe the parasite clearance 
curve are sufficient proxies for clinically-observed data.  While these measures could be 
used for modeling the parasite clearance curve, as of now they are far too rudimentary 
and would need to be adjusted at least for each drug or drug class; factors such as 
delivery method, host immunity, and dose would almost certainly need to be included as 
well. 
 For now, PC1/2 is best suited as an empirical descriptor of the parasite clearance 
curve, like PRR.  However, while PC1/2 has more opportunity to be adjusted to provide a 
mechanistic model of the clearance curve, PRR is more firmly entrenched in the 
literature, and, at the current juncture, PC1/2 does not provide any additional utility.  Pred* 
is based on the same assumption as PC1/2, and therefore should not be used in an 
explanatory capacity until it can be adjusted for covariates. 
Lag Phase 
 The lag phase is an interesting characteristic of the parasite clearance curve that 
has been described in greater theoretical detail elsewhere (Khoury et al., 2016).  We 
found that every drug class underwent a lag phase in some trials, which runs counter to 
the traditional classification of “fast” and “slow” acting drugs, but nonetheless conforms 
with the observation that even parasites treated with fast-actors are influenced to a great 
degree by pre-treatment growth patterns. 
 While artemisinins are considered the preeminent “fast-acting” antimalarials, we 
observed discrepancies in the precise time that artemisinin and its derivatives actually 
reach their peak effectiveness.  While it has been noted previously that measurements of 
clearance are subject to bias based on splenic clearance of dead and dying parasites 
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(Stepniewska et al., 2010), it can be assumed that all of the studies in these analyses are 
subject to similar biases and are therefore comparable, if not exactly numerically 
accurate. 
 It is our hope that such characterizations of lag may be useful in the future when 
trying to determine ideal antimalarial combination therapies.  The time of action of each 
drug alone, assuming it is related to the same measure when in combination with another 
drug, would be central to any combination therapy. 
 Initial parasitemia 
 Our results show no clear correlation within any drug group between PRR and 
initial parasitemia, but this relationship will be explored further.  Stratification drastically 
reduced the sample size, particularly for some drugs where data were already sparse.  In 
addition, parasite counts may decrease slightly even in severe cases of malaria due to 
quorum-sensing, immune activation, or sequestration.  As such, while we can draw no 
conclusions regarding correlations between initial parasitemia and kill rate, we may not 
have been able to capture the progression of the infection by using initial parasitemia 
alone. 
The utility of the results 
 We acknowledge that the explanatory power of these analyses is severely limited 
by the wide variation in a vast array of covariates.  Nevertheless, we feel that our results 
throw into question the canonical kill rates associated with each drug or drug class.  
While we would not criticize the ranking of each class according to average clearance 
rate, the value of the rate may both oversimplify the variation inherent in responses to 
treatment and inflate the rate to that of the best case scenario– most all trials featured 
rates approaching, but never quite reaching, these expected values. 
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 One potential application of this study would be an attempt to identify new 
combination therapies– perhaps including drugs analyzed here, or perhaps including a 
drug analyzed in the same method as the current study.  Hastings and Hodel (2014) 
described in some detail the various parameters that need to be considered when 
designing a new combination.  While many refer to the interaction between the 
constituent drugs, which would not be described adequately by these analyses, the fact 
remains that the better we can describe the action of a drug, the better we can deploy it. 
 An attempt to fit these results and data into the existing literature may be a 
mischaracterization of the goals of this endeavor.  Instead, we set out to collect the data 
around which other hypotheses in the field of malaria chemotherapy would be based.  We 
acknowledge that this aim is far from complete, with many studies yet to be included, 
drugs yet to be characterized, and variables yet to be analyzed.  Nonetheless, the results 
currently presented represent an affirmation of some paradigms widely embraced in 
malaria chemotherapy– namely, which drugs can be considered the fastest actors– as well 
as a reality check on others– for example, how some drugs rarely live up to their billing 
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Chapter 2: The effect of the stage of growth of P. 
berghei parasites on antimalarial kill rates 
Introduction 
 Numerous studies have identified antimicrobial resistance or decreased 
antimicrobial kill rate in bacteria in biofilms (Maira‐Litrán et al., 2000; Brooun et al., 
2000; Das et al., 1998) or in the stationary phase of growth (Eng et al., 1991).  It has thus 
been hypothesized that physiological changes associated with quorum-sensing, including 
altered gene expression and the induction of a stress response, mediate this reduced 
sensitivity to antibiotics (Mah and O’Toole, 2001; Brackman et al., 2011; Hentzer and 
Givskov, 2003; Udekwu et al., 2008).    The interaction between Plasmodium parasite 
density and antimalarial kill rates has yet to be observed. 
 In Chapter 1, we showed that there has been no clear relationship between initial 
parasitemia and kill rate within or across drugs or drug groups in P. falciparum 
monotherapy clinical trials.  However, the stratification performed in that analysis may be 
insufficient in that parasitemia is not strictly correlated with clinical status.  This could 
confound our previous analysis in two distinct ways, both described in the review article 
by White (1997).  First, relatively naïve patients could present with severe clinical 
malaria yet have a parasitemia undetectable by thin blood film; meanwhile, highly 
immune patients can exhibit asymptomatic hyperparasitemia.  If the pharmacokinetics or 
pharmacodynamics of a drug are affected by the patients clinical status, this would not be 
captured entirely by stratification of parasitemia because of the wide array of populations 
included in the analysis.  Second, following a phase of exponential growth, parasite 
counts in patients with untreated P. falciparum infections subside somewhat and reach a 
plateau.  This subsidence means that patients with parasites in the exponential and plateau 
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phases may be stratified together, despite the probability that the differing physiology of 
these parasites alters pharmacodynamics. 
 In this light, the question remains whether parasite density has any bearing on kill 
rate following treatment with antimalarials.  Parasite clearance immediately following 
treatment tends to follow a first-order decay pattern, suggesting that parasite density itself 
should not drive any discrepancy between early- and late-treated parasites.  The reduction 
in effectiveness of antibiotics on bacteria at high densities is attributed to quorum-
sensing.  A two-component system for response to environmental changes has been 
observed in intra-erythrocytic P. falciparum parasites (Wu et al., 2016), so similar 
physiologic changes could beget delayed parasite clearance following treatment during 
the plateau phase.  Other explanations for this phenomenon could include those hinging 
on the clinical status of the subject, like splenic or immune function; the stress response 
of the parasite (Dogovski et al., 2015); the shifting preference for host cell from 
normocytes to reticulocytes during late-stage infection (Singer, 1954); or the interaction 
between the parasite and host in a changing oxidative milieu (Becker et al., 2004). 
 In order to identify a relationship between the progression of the Plasmodium 
infection and the initial kill rate following treatment, we used a murine model infected 
with P. berghei and treated at one of several points throughout the progression of the 
parasitemia.  In doing so, we are able to observe differential parasite clearance curves, as 
well as compare outcomes, according to the progression of infection while controlling the 




 All mice used for this experiment were naïve BALB/C mice from Jackson Labs 
between 6 and 8 weeks old.  Mice were housed in cages with no more than 5 mice per 
cage, kept at approximately 76ºF, and provided food and water ad libitum. 
 All mice were infected with Plasmodium berghei ANKA strain parasites 
expressing the GFP-luciferase reporter and were treated with a single drug in a cytocidal 
model.  Parasites were low-passage (i.e., less than 5 passages through mice before being 
passed through mosquitoes) in order to ameliorate the effects of selection on the 
parasites. Donor mice were either infected directly from a frozen stock or were untreated 
mice from previous experimental arms.  In the latter case, 500,000 parasites were 
transferred from the donor to each naïve mouse.  In most cases, the parasites transferred 
from the donor would have been in the plateau phase, but were given ample time before 
treatment to establish log growth in the recipient mice.  The passage number of the 
parasites through mice for each experiment arm is depicted in Figure 2.1.  All study arms 
contained groups of three mice.  Inoculation of naïve mice from donors that had been 
infected for at least 6 days, as well as the observation from Vanderberg (1982) justify our 
assumption that all infections were asynchronous. 
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Figure 2.12  Passage (P) of parasites through mice for each experiment 
 The actual allocation schedule and parasite counts for all mice at the time of 
treatment are listed in Table 2.1. 
 
Figure 2.13  Projected allocation and dosing schedule, arrows represent allocation and 
initiation of treatment during Experiment 1; in Experiments 2 and 3, mice were only 
allocated to treatment groups on day 4 or day 8 after treatment.  Following the inflection 
point between log phase and plateau phase (often about day 4-6 following infection), 
there is more variation in the pattern of growth.  In some study arms, the projection 
needed to be translated horizontally to accommodate slower-progressing infections, but 
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Day 3 Day 3 Day 4 Day 6 Day 8 Day 10 
14584.7 120792.4 1000597.5 215098.5 1149490.7 3293605.2 
1.1 AQ 
 Day 5 Day 5 Day 7 Day 9 Day 11 
 295456.9 1310800.5 196791.2 228942.2 6197825.8 
1.2 PYN 
Day 3 Day 4 Day 5 Day 7 Day 9 Day 11 
10292.4 92271.7 152340.4 862990.7 6910700.4 5029720.9 
2 
AS 
  Day 4  Day 8  
  111772.0  362736.1  
AQ 
  Day 4  Day 8  
  77732.8  405735.3  
PYN 
  Day 4  Day 8  
  115715.7  466588.6  
3 
AS 
  Day 7  Day 11  
  1725070.2  15783932.6  
AQ 
  Day 7  Day 11  
  1503959.7  10718013.4  
PYN 
  Day 7  Day 11  
  1553873.9  11910179.4  
Table 2.5  Parasite counts (in parasites/µL, measured by luciferase assay) at the time of 
treatment initiation for all treatment groups in all study arms.  The parameters by which 
the groups were allocated are estimates based on the expected growth of untreated 
parasites.  The exact timing of dosing is described in the methods for each experiment.  
Within each band, the cells in the top row are the day on which the mice in that group 
actually initiated treatment, while the bottom cells are the geometric mean of the 3 mice 
in each group. 
 The mice in these studies were treated with monotherapy regimens of either 
artesunate, amodiaquine, or pyronaridine.  The drugs were prepared from powder stocks.  
Artesunate was dissolved in 5% sodium bicarbonate, while amodiaquine and 
pyronaridine were dissolved in deionized water.  The solutions were refrigerated until 
use.  All doses were administered via intraperitoneal injection. 
Data collection and analysis 
 All mice were sampled once daily for 14 days following treatment and then every 
other day until at least day 30 following treatment.  On the first day of drug dosing, 
unless otherwise noted, mice were sampled concurrently with treatment and then at 3, 6, 
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and 12 hours following treatment.  Additional samples or slight deviations from this 
schedule were noted and are reflected in the data presented. 
 We collected 5 µL of tail blood at each sampling point and immediately added it, 
in a 1:9 ratio, to lysis buffer (20 mM Tris, 5 mM EDTA, 0.008% saponin, 0.08% Triton 
x-100; pH=7.5) in a 96-well plate for analysis by luciferase assay.  For analysis of the 
samples, 5 µL of this solution was added to 95 µL of a luciferase buffer (200 mM 
Tricine, pH=7.8; 10 mM EDTA, pH=8; 10 mM K2CO3, pH=7.8; 50 mM MgSO4; 250 
mM DTT; 25 mM ATP; 20 mM D-kuciferon) and photon emissions were recorded by the 
IVIS Spectrum In Vivo Imaging System and analyzed using Living Image software (v. 
4.4).  Until the assay was run, plates were stored at -76ºC.  A blood film was created once 
daily for each mouse (on days where blood samples were taken), regardless of its 
treatment status.  These blood films were stained with Giemsa stain and were used to 
corroborate luciferase assay results. Parasite counts were extracted from the results of the 
luciferase assay according to the standard curve described elsewhere (Walker and 
Sullivan, 2017). 
 The results were analyzed in GraphPad Prism by observation of raw clearance 
curves, as well as normalization to 100% of initial parasitemia.  In addition, Kaplan-
Meier survival curves were produced and t-tests calculated using GraphPad Prism 
(GraphPad Prism version 7.0b for Mac).  
Experiment 1 
 The first experiment, featuring three separate drug arms, with mice treated at 
10,000, 100,000 and 1,000,000 parasites/µL at roughly days 2, 3, and 4 post-infection for 
the log phase (Figure 2.2) as well as “late-treated” mice dosed during the plateau phase of 
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parasite growth on approximately day 6, 8 and 10 with parasitemia in the million 
parasites/µL range. 
Experiment 2 and 3 
 The protocol for the second experiment was designed based on the results from 
the first; rather than treating throughout the progression of the infection, we decided to 
simply treat mice on day 4 (between 50,000 and 500,000 parasites/µL) or day 8 (greater 
than a million parasites/µL)  post-infection before or after the inflection point between 
the log growth and plateau phases with different drug doses to see if the effect was 
enhanced.   
Results 
 The parasite counts at the time of treatment initiation, shown in Table 2.1, were 
comparable across and within all drug treatment groups for which treatment began at the 
same time.  The parasite growth in untreated mice is similar to that in humans, as 
described by White (1997); rapid expansion of the parasite population occurs over the 
first several life cycles at a roughly log-linear rate, and then growth slows and plateaus as 
parasite counts reach a certain threshold.  In mice, this threshold is about 5-10 million 
parasites/µL.  During this time, parasite counts may rise or fall slightly, but there is little 
change overall.  Log growth resumes around day 8-10.  Log and plateau phases are clear 
in all three groups in Experiment 1, with the transition from the former to the latter 
occurring at some point between the 4th and 6th day following infection (Figure 2.3).  
Untreated mice in Experiments 2 and 3 followed the same pattern (not shown). 
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Figure 2.14  Parasite growth of untreated mice in a) Experiment 1.0, b) Experiment 1.1, 
and c) Experiment 1.2.  The curve for each mouse is truncated at the time of initiation of 
treatment. 
 In most treatment groups, mice treated during the plateau phase exhibited slower 
clearance rates initially (Figure 2.4-7).  The discrepancy between the clearance curves of 
early- and late-treated mice tends to be visually apparent, and often reaches statistical 
significance at some early time points (α=0.05).  The difference in kill rates, however, 
does not translate to a difference in outcome. 
 Geometric means and geometric standard deviations among all three mice in a 
group (or those surviving to that point) are shown at each time point in every graph, 
while statistical tests were only performed on graphs featuring two clearance curves– one 
for an early-treated group and one for a late-treated group. 






















































Experiment 1– 50mg/kg AS at 0 and 24 hours; 120mg/kg AQ at 0 and 24 
hours, 60mg/kg AQ at 48 hours; or 60mg/kg PYN single dose  
The raw data, in parasites/µL, show a clear distinction in clearance times between early- 
and late-treated groups in mice treated with PYN, but the time to reach the limit of 
quantification is more uniform in the AS and AQ groups despite early differences in the 
slope of the clearance curve.  Despite apparent differences in clearance rate or clearance 
time, the overall number of parasites cleared does not appear to be affected, except in the 
case of the hyperparasitemic mice treated with AS (Group 6).  In order to better compare 
clearance rates, which are not correlated with initial parasitemia, the remainder of the 
results in this report will present a parasite count normalized to 100% of initial 
parasitemia for each group. 
 Following normalization, the discrepancies in clearance rates between early- and 
late-treated mice becomes apparent in those treated with AS.  While the difference in 
slope is smaller in the AQ and PYN groups, the early-treated groups do have a slightly 
faster clearance rate than the late-treated groups over the first several hours (Figure 2.4).  
Group 4 in the AQ-treated mice, which were treated on day 7 following infection, are the 
obvious exception to this general trend. 
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Figure 2.15  Parasite counts, normalized to 100% of initial parasitemia, for mice treated 
at various points along the progression of infection for the first two days following 
treatment with a) 50mg/kg AS twice q24, b) 120mg/kg AQ twice q24 followed by 60mg/kg 
AQ on the third day, or c) 60mg/kg PYN in a single dose.  The parameters listed in the 
figure legend by which the groups were allocated are estimates based on the expected 
growth of untreated parasites.  The exact timing of dosing is described in the methods for 
each experiment; groups should be considered comparable across drugs. 
 These data, while demonstrating a distinction in clearance rates between early- 
and late-treated mice, failed to exhibit parasitemia-dependent kill rates.  We felt that it 
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would, therefore, be sufficient to treat mice only on day 4 (during the log-growth phase) 
or day 8 (roughly the same parasitemia during the plateau phase). 
Experiments 2 and 3 
 The results of Experiment 1 warranted further investigation into the difference in 
clearance rates of early- and late-treated mice.  However, the apparent clustering of early- 
and late-treated groups suggested that we need not observe clearance rates at various 
steps though the infection of progression (Figure 2.4), but instead only need choose 
representative treatment start times from the log-growth and plateau phases.  The results 
in Figure 2.5 are clearance curves of only selected groups from Experiment 1 with the 
results of t-tests performed on each point. 
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Figure 2.16  Selected clearance curves from Figure 2.4 illustrating discrepancies in 
clearance rates depending on whether treatment was initiated during log-growth or 
plateau phase. a) 50mg/kg AS twice q24, starting on either day 4 or day 8 following 
infection; b) 120mg/kg AQ twice q24 followed by 60mg/kg AQ on the third day, starting 
on either day 5 or day 9 following infection; or c) 60mg/kg PYN in a single dose, starting 
on either day 4 or day 9 following infection. 
 We felt that lowering the doses of the quinolines may help distinguish early- and 
late-treated mice.  Therefore, the study arms in this experiment feature intermediate 
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(Experiment 2) and low (Experiment 3) doses of quinolines.  Because AS treatment 
already exhibited a significant discrepancy between the early and late groups, and 
because 50mg/kg was already non-curative, we did not lower the dose of AS 
administered; instead, we altered the regimen such that the mice received more frequent 
doses (Experiment 2) or a single dose (Experiment 3). 
Experiment 2– 50mg/kg AS at 0, 8, and 16 hours; 50mg/kg AQ single dose; 
or 10mg/kg PYN single dose 
 At the intermediate quinoline doses used in this study arm, there appeared to be a 
far less marked distinction between early- and late-treated groups; similarly, more 
frequent AS dosing may have mitigated the effect we observed previously (Figure 2.6).  
Nevertheless, the difference in percentage of parasites remaining was large enough to 
reach statistical significance at one or more time points in the first 4 hours in each 
treatment group.  Once again, the timing of the initiation of treatment was unrelated to 
the recurrence of parasitemia or survival outcome. 
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Figure 2.17  Percentage of parasites remaining following treatment during the log-
growth phase (4 days after infection) or plateau phase (8 days after infection).  Mice 
were treated with a) 50mg/kg AS three times q8; b) 50mg/kg AQ as a single dose; or c) 
10mg/kg PYN as a single dose. 
Experiment 3– 50mg/kg AS single dose; 10mg/kg AQ single dose; or 5mg/kg 
PYN single dose 
 A further decrease in dose again showed a difference in initial kill rate without an 
associated change in recrudescence or outcome (Figure 2.7).  Because these doses are 
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sub-curative, there is somewhat more variation in the magnitude of the response at later 
time points, but statistically significant differences in clearance rates were obtained in 
AS- and AQ treated mice within the first 2 days after treatment; as with Experiment 1, 
though PYN-treated mice did not reach a statistically significant discrepancy between 




Figure 2.18  Percentage of parasites remaining following treatment during the log-
growth phase (7 days after infection) or plateau phase (11 days after infection).  Mice 
were treated with a) 50mg/kg AS as a single dose; b) 10mg/kg AQ as a single dose; or c) 
5mg/kg PYN as a single dose. 
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 Because two AS-treated groups showed clear differences between early- and late-
treated groups, while the AS-treated mice in Experiment 2 were somewhat more similar, 
we chose to pool these data to see if the aggregated results still showed the distinction.  
Our observations only extend for the first 8 hours after treatment, because after this point 
the treatment regimens began to differ.  We used data from groups 3 and 5 from 
Experiment 1.0, as well as all of the AS data from Experiments 2 and 3.  Despite the 
different doses, each early-treated mouse had cleared a greater percentage of its parasites 
than each late-treated mouse at every time point, (Figure 2.8). 
 Using GraphPad Prism, we performed a non-linear regression with the y-intercept 
constrained such that it was equal to 100 for each group.  We then compared the slopes of 
the resulting log-linear lines using a sum-of-squares F test.  The slopes of the early- and 
late-treated groups are statistically distinct (p<0.0001).  In addition, the r2 value of the 
late-treated group indicates a much poorer correlation of these values (Figure 2.8).  The 
same analyses were performed for the AQ- and PYN-treated groups.  While these early- 
and late-treated groups were not as divergent as in the AS groups, the early clearance 




Figure 2.19  Pooled data from the first 8 hours following treatment in a) AS-treated mice 
from Experiment 1.0 (early: treated on day 4; late: treated on day 8), Experiment 2 
(early: day 4; late: day 4), and Experiment 3 (early: day 7; late: day 11); b) AQ-treated 
mice from Experiment 1.1 (early: treated on day 5; late: treated on day 9), Experiment 2 
(early: day 4; late: day 4), and Experiment 3 (early: day 7; late: day 11); c) PYN-treated 
mice from Experiment 1.2 (early: treated on day 4; late: treated on day 9), Experiment 2 
(early: day 4; late: day 4), and Experiment 3 (early: day 7; late: day 11).  Regression 
and statistical tests were performed using GraphPad Prism. 
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 We looked at all of our results to observe a correlation between initial parasitemia 
and clearance rate, represented by either 6- or 8-hour parasite reduction ratio (PRR).  In 
Experiment 1 (Figures 2.9a-c) and Experiment 3 (Figures 2.9g-i), samples were taken at 6 
hours following treatment, allowing calculation of a 6-hour PRR; in Experiment 2 
(Figures 2.9d-f), the closest sample was taken at 8 hours.  While there may be a small 
correlation between PRR and initial parasite count, it appears that the phase of growth is 
a far more important factor.  We can conclude this because in most cases, even when late-
treated groups exhibited a smaller PRR, they tend to cluster horizontally according to 
growth stage.  This indicates that for each drug there is a PRR that is characteristic of the 
plateau phase of growth rather than a given starting parasite count.  In the latter case, we 
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Figure 2.20  Initial parasite count compared to early PRR (6- or 8-hours following 
treatment).  a) Experiment 1.0, 50mg/kg AS twice q24; b) Experiment 1.1 120mg/kg AQ 
twice q24 followed by 60mg/kg AQ on the third day; c) Experiment 1.2, 60mg/kg PYN in 
a single dose; d) Experiment 2, 50mg/kg AS as a single dose; e) Experiment 2, 10mg/kg 
AQ as a single dose; f) Experiment 2 5mg/kg PYN as a single dose; g) Experiment 3, 
50mg/kg AS as a single dose; h) Experiment 3, 10mg/kg AQ as a single dose; i) 
Experiment 3, 5mg/kg PYN as a single dose. 
 Finally, we normalized treatment day to the center of the transition between log 
and plateau growth.  Using the growth curves from the untreated mice in each group, we 
performed a non-linear regression with GraphPad to fit a quadratic polynomial to the 
region immediately surrounding the suspected inflection point.  The point of inflection 
for the whole group was defined as the x-value (time) at which the apex of the parabola 
lied.  For all three drugs, but most significantly for AS and PYN, there is a clear 
downward trend as treatment is started later in the course of infection (Figure 2.10). 
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Figure 2.21  PRR (either 6- or 8-hour ratio, depending on sampling pattern in the study 
arm) in mice treated at different points throughout the course of infection.  In order to 
better compare study arms with disparate parasite growth phenotypes prior to treatment, 
the timing of the initiation of treatment was normalized to the point of transition between 
the log and plateau growth phases. a) all AS-treated mice, b) all AQ-treated mice, c) all 
PYN-treated mice. 
Discussion 
 We feel that our results are sufficient to suggest a relationship between the stage 
of growth of the P. berghei parasites and the kill rate immediately following treatment.  
Further, our results may suggest a continuous decline in kill rate as the infection 
progresses.  This relationship could hold clinical relevance in that, while it is always 
preferable to quickly reduce parasitemia, rapid clearance of parasites is especially vital in 
cases of severe malaria, because most deaths occur in the first 24 hours.  Therefore, it is 
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essential to understand any differences between the clearance kinetics in complicated, 
hyperparasitemic infections and uncomplicated infections so each can be optimally 
treated. 
 Few studies in humans have aimed to compare the treatment of hyperparasitemic 
malaria with cases of lower parasite density.  One such study reported an increased 
instance of severe resistance to treatment among the hyperparasitemic patients (Sowunmi 
et al., 2004).  Our results were not in accordance with a traditional definition of 
resistance, as the outcome did not seem to be affected by the timing of the initiation of 
treatment.  Nevertheless, the delay in parasite clearance observed in our studies could be 
associated with an increased risk of treatment failure.  Importantly, however, our study 
did not recover a significant correlation between kill rate and parasitemia; instead, the 
duration of the infection prior to treatment seemed to be a better prognostic indicator.  
This relationship is even less well documented in human patients.  A suitable proxy may 
be the distance patients must travel to reach professional clinics, as distance from a clinic 
is positively correlated with a delay in treatment seeking (Glik et al., 1989; Ettling et al., 
1989; Kaewsonthi et al., 1986).  This relationship has not been studied from a 
pharmacodynamics standpoint. 
 Despite reaching statistical significance at several points throughout the first 2 
days following treatment, the difference in clearance by early- and late-treated mice was 
sometimes unclear.  While our data did not observe that late-treated mice clear parasites 
faster, there were some data that suggested, perhaps, that the clearance rates were the 
same.  For PYN and AS, we assume that the lack of discrepancy between early- and late-
treated mice can be attributed to the extraordinary rate of action of these drugs; their 
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characteristic clearance rates must approach the maximum splenic clearance rate even in 
late-treated mice, so early-treated mice cannot increase this rate greatly.  We also 
observed much greater variation in the early clearance rates of late-treated mice, which 
could be both a phenotypic feature of treatment during the plateau phase and a reason for 
the ambiguity in the comparisons of some of our clearance curves. 
 The clearance curves of early- and late-treated mice, treated with any of the three 
drugs, are reminiscent of the delayed parasite clearance phenotype observed during 
artemisinin therapy in Southeast Asia– an increased parasite clearance half-life and 
clearance time, but little or no associated reduction in cure rate (Dondorp et al., 2011).  
Mutations in the K13 gene, associated with this phenotype in P. falciparum, is unlikely to 
be the causative agent of our observations (Cao et al., 2017).  Nevertheless, Dogovksi et 
al (2015) hypothesized that K13 mutations are associated with enhanced antioxidant 
stress responses and explained that the mechanism of action of DHA, the bioactivated 
form of artemisinin and its derivatives, is similar to the traditional cell stress response.  
Mok et al (2014) hypothesized that the upregulation of the unfolded protein response as a 
result of K13 mutation allows for an increased capacity of the parasite to repair or 
remove proteins, counteracting the action of the drug.  In our context, it is possible that 
quorum sensing activation initiates a similar cell stress response, giving the parasites a 
head start in their ability to repair damaged proteins and stave off death.  
Transcriptionally, this could be tested in the log phase of growth compared to the plateau 
phase. 
 Canonically speaking, this hypothesis is primarily applicable to artemisinin 
treatment, and therefore would only explain the delayed clearance in our AS trials.  
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However, the cell stress responses are also involved in the killing mechanism of the 
aminoquinolines, such as AQ and PYN, because they inhibit hemozoin formation.  Free, 
non-detoxified heme leads to the formation of various reactive oxygen species (Francis et 
al., 1997; Freinbicherler et al., 2011), necessitating activation of the antioxidant response.  
Further, the immune response itself can alter the redox balance between the parasite and 
the host (Becker et al 2003).  Dogovski et al (2015) showed synergy between DHA and 
epoximycin, a proteasome inhibitor; a similar experiment to see if the discrepancies 
shown in the present study are ameliorated would be worthwhile. 
 In addition to the changing milieu in the parasite and host as the infection 
progresses, the host preference of P. berghei shifts from normocytes to reticulocytes in 
late-stage infections, eventually reaching a preference for reticulocytes of about 150-fold 
over that of normocytes (Singer, 1954; Cromer et al., 2006).  The physiology of 
reticulocytes could contribute to the altered pharmacodynamics in late-treated mice.  
Srivastava et al (2015) hypothesize that the extensive metablome of reticulocytes 
provides resource reserves for P. berghei and P. vivax parasites (which exhibit preference 
for reticulocytes), potentially dampening the effect of the drugs on the parasites.  In 
addition, human reticulocytes have greater antioxidant activity than normocytes, so the 
transition in host cell preference could also slow kill rates in much the same way as the 
parasite antioxidant response as hypothesized above (Sailaja et al 2003).  If our 
observation that later initiation of treatment results in slower initial kill rates is dependent 
on an intrinsic characteristic of reticulocytes, then we may be unable to extrapolate to P. 
falciparum.  P. falciparum also shows some preference for reticulocytes, but there is 
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some evidence to suggest that it becomes less selective at higher parasitemias (Simpson 
et al., 1999). 
 We also thought it possible that the delay in maximum clearance observed 
particularly in the late-treated AS groups was due to altered pharmacokinetics.  The 
pharmacokinetics of AS in severely ill human patients has been compared to that in those 
with uncomplicated infections, and while AS exhibited a slightly shorter half-life in 
severe infections, the half-life of DHA was not significantly affected (Li et al., 2005).  
Similar studies are not available for AQ or PYN, but because all three drugs exhibited a 
correlation with progression of infection, the parsimonious explanation would be one in 
which all three are affected by the same mechanism.  We therefore conclude that altered 
pharmacokinetics are not sufficient to cause such an altered clearance phenotype. 
 It is noteworthy that, in Experiment 1.0, the clearance action of AS is delayed for 
about 6 hours, well beyond the mean residence time for AS or DHA (Davis et al., 2001).  
In the absence of altered pharmacokinetics, this is suggestive of an enhanced dependence 
on a delayed antibiotic effect, wherein damaged parasites either do not die or are not 
cleared for some time following exposure to drug. 
 Assuming these trends hold in P. falciparum infection, our results would again 
underscore the importance of early detection and treatment of malaria infection.  In 
addition, this characterization of the parasite clearance curve, for these and other drugs 
that may be studied in the future, may help inform the ideal course of treatment in severe 
or hyperparasitemic malaria.  Because clearance of Plasmodium parasites during 
chemotherapy appears to depend in some capacity on quorum sensing, our current 
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treatment regimens may be inadequately attuned to the changing physiology of the 
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